Wells Fargo & Company Palisade Bio, Inc. Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.11 - $83.85 $34 - $26,664	318 Added 1.94%	16,684 $2,000
Q2 2022 Aug 12, 2022	BUY	$0.41 - $1.04 $25 - $64	62 Added 0.38%	16,366 $7,000
Q1 2022 May 16, 2022	BUY	$0.81 - $1.51 $8,103 - $15,106	10,004 Added 158.79%	16,304 $17,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $2.96 $13 - $29	10 Added 0.16%	6,300 $8,000
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.93 $14,217 - $23,776	6,050 Added 2520.83%	6,290 $16,000
Q2 2021 Aug 16, 2021	BUY	$3.49 - $11.34 $837 - $2,721	240 New	240 $1,000

Ticker PALI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,240,200
Market Cap $254M
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzym...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.